Health Canada Warns: Do Not Use Jin Bu Huan Anodyne Tablets
Health Canada is warning consumers not to use the unauthorized product Jin Bu Huan Anodyne because it contains the undeclared ingredient tetrahydropalmatine, which has been associated with serious adverse health effects.
The amount of tetrahydropalmatine in a daily dose of Jin Bu Huan Anodyne tablets has been associated with reports of liver injury in adults, and reports of neurotoxicity (brain and nervous system injury) in children and adults. Tetrahydropalmatine has also been associated with adverse reactions such as fever, nausea, vomiting, abdominal pain, and diarrhoea.
In addition to containing an undeclared ingredient, Jin Bu Huan Anodyne's product label promotes an unauthorized use in the treatment of ulcer pain, and abdominal pain after childbirth. Use of this unauthorized product to treat these conditions may result in patients delaying effective treatments required for their conditions.
Jin Bu Huan Anodyne tablets are not authorized for sale in Canada. Authorized health products will bear an eight-digit Drug Identification Number (DIN), a Natural Product Number (NPN), or a Homeopathic Drug Number (DIN-HM). This authorization indicates that the products have been assessed by Health Canada for safety, effectiveness and quality.
Wing Quon Enterprises Ltd., the Canadian importer of Jin Bu Huan Anodyne tablets, has initiated a recall of the product. Health Canada will continue to monitor the effectiveness of this recall.
Consumers who have taken Jin Bu Huan Anodyne tablets should discontinue use immediately and consult a health care professional for advice on effective treatments for their conditions. Canadian retailers are advised to remove this product from their shelves.